2
Announcements
Trials
Browse
Landscape
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Breast Neoplasms
9
Neoplasms
7
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
5
Multiple Myeloma
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Lymphoma
3
Leukemia, Myeloid, Acute
3
Leukemia
3
Esophageal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Brain Neoplasms
3
Sarcoma
2
Rectal Neoplasms
2
Radiation Injuries
2
Prostatic Neoplasms
2
Preleukemia
2
Precancerous Conditions
2
Osteosarcoma
2
Neoplasms by Histologic Type
2
Nasopharyngeal Carcinoma
2
Myelodysplastic Syndromes
2
Multiple Chronic Conditions
2
Melanoma
2
Lymphoproliferative Disorders
2
Lymphatic Diseases
2
Lung Neoplasms
2
Leukemia, Myeloid
2
Leukemia, Lymphoid
2
Leukemia, Biphenotypic, Acute
2
Interventions
Pemetrexed
9
Nivolumab
8
Cisplatin
8
Carboplatin
8
pembrolizumab
7
130-nm albumin-bound paclitaxel
7
Gemcitabine
6
padeliporfin
5
durvalumab
5
Paclitaxel
5
Bevacizumab
5
palbociclib
4
napabucasin
4
atezolizumab
4
Irinotecan
4
Fulvestrant
4
Fluorouracil
4
Drug Therapy
4
Cyclophosphamide
4
ribociclib
3
osimertinib
3
cobimetinib
3
alectinib
3
abemaciclib
3
Trastuzumab
3
Sunitinib
3
Radiosurgery
3
Mitomycin
3
Docetaxel
3
Cetuximab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Site
×
Patient Reported Outcome Measures
×
Clear all
NCT03053297
2018-02-08
PANORAMA
AstraZeneca
Terminated
89 enrolled